The role of dopamine in the behavioral effects of caffeine in animals and humans

Pharmacology Biochemistry and Behavior

Volumn 57, Issue 3, 1997, Pages 533-541

  Garrett, Bridgette E ^a   Griffiths, Roland R ^a  

^a Behav Pharmacology Research Unit   (United States)

Author keywords

Adenosine; Behavioral methods; Caffeine; Dopamine; Human; Mechanisms of action; Nonhuman primates; Psychomotor stimulants; Rats

Indexed keywords

ADENOSINE RECEPTOR; AMPHETAMINE; CAFFEINE; COCAINE; DOPAMINE; DOPAMINE RECEPTOR;

ARTICLE; BEHAVIOR; CIRCLING BEHAVIOR; DISCRIMINATIVE STIMULUS; DOPAMINERGIC ACTIVITY; DOSE RESPONSE; DRUG COMPARISON; DRUG DEPENDENCE; DRUG SELF ADMINISTRATION; HUMAN; LOCOMOTION; NONHUMAN; PRIORITY JOURNAL; REINFORCEMENT;

ANIMALS; CAFFEINE; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LOCOMOTION;

ANIMALIA; PRIMATES;

EID: 0030754563     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(96)00435-2     Document Type: Article

References (125)

1. Abbracchio M. P., Colombo F., Di Luca M., Zaratin P. Cattanbeni, F. Adenosine modulates the dopaminergic function in the nigro-striatal system by interacting with striatal dopamine dependent adenylate cylase. Pharmacol. Res. Commun. 19:1987;275-286.
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994.
3. Arnaud M. J. The pharmacology of caffeine. Prog. Drug. Res. 31:1987;272-313.
4. Barone J., Roberts H. Human consumption of caffeine. Dews P. B. Caffeine perspectives from recent research. 1984;59-73 Springer, Berlin.
5. Bianchi C. P. The effect of caffeine on radiocalcium movement in the frog sartorius. J. Gen. Physiol. 44:1961;845-858.
6. Brauer L. H., de Wit H. Role of dopamine in d-amphetamine-induced euphoria in normal healthy volunteers. Exp. Clin. Psychopharmacol. 3:1995;371-381.
7. Callahan P. M., Appel J. B., Cunningham K. A. Dopamine D1 and D2 mediation of the discriminative stimulus properties of d-amphetamine and cocaine. Psychopharmacology. 103:1991;50-55.
8. Cardinali D. P. Methylxanthines. Possible mechanisms of action in the brain Trends Pharmacol. Sci. 1:1980;405-407.
9. Carney J. M. Effects of caffeine, theophylline and theobromine on scheduled controlled responding in rats. Br. J. Pharmacol. 75:1982;451-454.
10. Casas M., Ferré S., Cobos A., Grau J.-M., Jané F. Relationship between rotational behavior induced by apomorphine and caffeine in rats with unilateral lesion of the nigrostriatal pathway. Neuropharmacology. 28:1989;407-409.
11. Chait L. D., Johanson C. E. Discriminative stimulus effects of caffeine and benzphetamine in amphetamine-trained volunteers. Psychopharmacology. 96:1988;302-308.
12. Chait L. D., Uhlenhuth E. H., Johanson C. E. The discriminative stimulus and subjective effects of d-amphetamine in humans. Psychopharmacology. 86:1985;307-312.
13. Choi O. H., Shamim M. T., Padgett W. L., Daly J. W. Caffeine and theophylline analogues. Correlation of behavioral effects with activity as adenosine receptor antagonists and as phosphodiesterase inhibitors Life Sci. 43:1988;387-398.
14. Daly J. W. Mechanism of action of caffeine. Garattini S. Caffeine, coffee and health. 1993;97-150 Raven Press, New York.
15. Daly J. W., Bruns R. E., Snyder S. H. Adenosine receptors in the central nervous system. Relationship to the central actions of methylxanthines Life Sci. 28:1981;2083-2097.
16. de Wit H., Uhlenhuth E. H., Johanson C. E. Individual differences in the reinforcing and subjective effects of amphetamine and diazepam. Drug Alcohol Depend. 16:1986;341-360.
17. Evans S. M., Critchfield T. S., Griffiths R. R. Caffeine reinforcement demonstrated in a majority of moderate caffeine users. Behav. Pharmacol. 5:1994;231-238.
18. Evans S. M., Griffiths R. R. Dose-related caffeine discrimination in normal volunteers. Individual differences in subjective effects and self-reported cues Behav. Pharmacol. 2:1991;345-356.
19. Evans S. M., Griffiths R. R. Caffeine tolerance and choice in humans. Psychopharmacology. 108:1992;51-59.
20. 2 receptors in the neostriatum. Brain Res. 594:1992;124-130.
21. Ferré S., Fuxe K., von Euler G., Johansson B., Fredholm B. B. Adenosine-dopamine interactions in the brain. Neuroscience. 51:1992;501-512.
22. Ferré S., Herrera-Marschitz M., Grabowska-Anden M., Ungerstedt U., Casas M., Anden N.-E. Postsynaptic dopamine/adenosine interaction. I. Adenosine analog inhibits dopamine D2-mediated behavior in short-term reserpinized mice. Eur. J. Pharmacol. 192:1991;30-35.
23. 1 receptor-mediated mechanisms. Eur. J. Neurosci. 8; 1996, 8:1996;1545-1553.
24. Ferré S., Popolli P., Giménez-Llort L., Finnman U.-B., Martínez E., de Carolis A. S., Fuxe K. Postsynaptic antagonistic interaction between adenosine A1 and dopamine D1 receptors. NeuroReport. 6:1994;73-76.
25. 2 receptors in the neostriatum. Psychopharmacology. 116:1994;279-284.
26. Ferré S., von Euler G., Johansson B., Fredholm B., Fuxe K. Stimulation of high affinity A-2 receptors decrease the affinity of dopamine D-2 receptors in rat striatal membranes. Proc. Natl. Acad. Sci. USA. 88:1991;7237-7241.
27. Finn I. B., Holtzman S. G. Tolerance to caffeine-induced stimulation of locomotor activity in rats. J. Pharmacol. Exp. Ther. 238:1986;542-546.
28. Finn I. B., Iuvone P. M., Holtzman S. G. Depletion of catecholamines in the brain of rats differentially affects stimulation of locomotor activity by caffeine, d-amphetamine, and methylphenidate. Neuropharmacology. 29:1990;625-631.
29. Fischman M. W., Foltin R. W., Nestadt G., Pearlson G. D. Effects of desipramine maintenance on cocaine self-administration by humans. J. Pharmacol. Exp. Ther. 253:1990;760-770.
30. Fischman M. W., Schuster C. R., Javid J., Hatano Y., Davis J. Acute tolerance to the cardiovascular and subjective effects of cocaine. J. Pharmacol. Exp. Ther. 235:1985;677-682.
31. Fischman M. W., Schuster C. R., Resnekov L., Shick J. F. E., Krasnegor N. A., Fennel W., Freedman D. X. Cardiovascular and subjective effects of intravenous cocaine administration in humans. Arch. Gen. Psychiatry. 33:1976;983-989.
32. Foltin R. W., Fischman M. W. Assessment of abuse liability of stimulant drugs in humans. A methodological survey Drug Alcohol Depend. 28:1991;3-48.
33. Fredholm B. B. Are methylxanthine effects due to antagonism of endogenous adenosine? Trends Pharmacol. Sci. 2:1980;129-132.
34. Fredholm B. B. Adenosine and central catecholamine neurotransmission. Stefanovich V., Rudolphi K., Schubert P. Adenosine. Receptors and modulation of cell function:1985;91-104 IRL Press, Oxford, UK.
35. Fredholm B. B. Adenosine, adenosine receptors and the actions of caffeine. Pharmacol. Toxicol. 76:1995;93-101.
36. Fredholm B. B., Herrera-Marschitz M., Jonzon B., Lindstrom K., Ungerstedt U. On the mechanisms by which methylxanthines enhance apomorphine-induced rotation behavior in the rat. Pharmacol. Biochem. Behav. 19:1983;535-541.
37. Fuxe K., Ungerstedt U. Action of caffeine and theophylline on supersensitive dopamine receptors. Considerable enhancement of receptor response to treatment with DOPA and dopamine receptor agonists Med. Biol. 52:1974;48-54.
38. Garrett B. E., Holtzman S. G. D1 and D2 dopamine receptor antagonists block caffeine-induced stimulation of locomotor activity in rats. Pharmacol. Biochem. Behav. 47:1994;89-94.
39. Garrett B. E., Holtzman S. G. Caffeine cross-tolerance to selective dopamine receptor agonists but not to their synergistic interaction. Eur. J. Pharmacol. 262:1994;65-75.
40. Garrett B. E., Holtzman S. G. Does adenosine receptor antagonism mediate caffeine-induced rotational behavior? J. Pharmacol. Exp. Ther. 274:1995;207-214.
41. Gauvin D. V., Criado J. R., Moore K. R., Holloway F. A. Potentiation of cocaine's discriminative effects by caffeine. A time-effect analysis Pharmacol. Biochem. Behav. 36:1990;195-197.
42. Gauvin D. V., Harland R. D., Michaelis R. C., Holloway F. A. Caffeine-phenylethylamine combinations mimic the cocaine discriminative cue. Life Sci. 44:1989;67-73.
43. Gauvin D. V., Holloway F. A. The subjective effects of caffeine. Bridging the gap between animal and human research Pharmacopsychoecologia. 7:1994;179-200.
44. Gilbert R. M. Caffeine consumption. Spiller G. A. The methylxanthine beverages and food. Chemistry, consumption, and health effects:1984;185-213 Alan R. Liss, New York.
45. Govoni S., Petkov V. V., Montefusco C., Missale C., Battaini F., Spano P. F., Trabucchi M. Differential effects of caffeine on dihydroxyphenylacetic acid concentrations in various rat brain dopaminergic structures. J. Pharm. Pharmacol. 36:1984;458-460.
46. Griffiths R. R., Bigelow G. E., Henningfield J. E. Similarities in animal and human drug-taking behavior. Mello N. K. Advances in substance abuse, vol. 1. 1980;1-90 JAI Press, Greenwich, CT.
47. Griffiths R. R., Bigelow G. E., Liebson I. A. Human coffee drinking. Reinforcing and physical dependence producing effects of caffeine J. Pharmacol. Exp. Ther. 239:1986;416-425.
48. Griffiths R. R., Bigelow G. E., Liebson I. A., O'Keeffe M., O'Leary D., Russ N. Human coffee drinking. Manipulation of concentration and caffeine dose J. Exp. Anal. Behav. 45:1986;133-148.
49. Griffiths R. R., Brady J. V., Bradford L. D. Predicting the abuse liability of drugs with animal drug self-administration procedures. Psychomotor stimulants and hallucinogens Thompson T., Dews P. B. Advances in behavioral pharmacology, vol. 2. 1979;163-208 Academic Press, New York.
50. Griffiths R. R., Evans S. M., Heishman S. J., Preston K. L., Sannerud C. A., Wolf B., Woodson P. P. Low-dose caffeine discrimination in humans. J. Pharmacol. Exp. Ther. 252:1990;970-978.
51. Griffiths R. R., Mumford G. K. Caffeine - A drug of abuse? Bloom F. E., Kupfer D. J. Psychopharmacology. The fourth generation in progress:1995;1699-1713 Raven Press, New York.
52. Griffiths R. R., Mumford G. K. Caffeine reinforcement, discrimination, tolerance and physical dependence in laboratory animals and humans. Schuster C. R., Kuhar M. J. Pharmacological aspects of drug dependence. Toward an integrated neurobehavioral approach:1996;315-341 Springer-Verlag, Handbook of experimental pharmacology. New York.
53. Griffiths R. R., Woodson P. P. Caffeine physical dependence. A review of human and laboratory animal studies Psychopharmacology. 94:1988;437-451.
54. Griffiths R. R., Woodson P. P. Reinforcing effects of caffeine in humans. J. Pharmacol. Exp. Ther. 246:1988;21-29.
55. Gunne L.-M., Anggard E. Pharmacokinetic studies with amphetamine - Relationship to neuropsychiatric disorders. J. Pharmacokinet. Biopharmacol. 1:1973;481-495.
56. Hale K. L., Hughes J. R. Caffeine self-administration and subjective effects in adolescents. Exp. Clin. Psychopharmacol. 3:1995;364-370.
57. Harland R. D., Gauvin D. V., Michaelis R. C., Carney J. M., Seale T. W., Holloway F. A. Behavioral interaction between cocaine and caffeine. A drug discrimination analysis in rats Pharmacol. Biochem. Behav. 32:1989;1017-1023.
58. Henningfield J. E., Lukas S. E., Bigelow G. E. Human studies of drugs as reinforcers. Goldberg S. R., Stolerman I. P. Behavioral analysis of drug dependence. 1986;69-122 Academic Press, Orlando, FL.
59. Herrera-Marschitz M., Casas M., Ungerstedt U. Caffeine produces contralateral rotational behavior in rats with unilateral dopamine denervation. Comparisons with apomorphine-induced responses Psychopharmacology. 94:1988;38-45.
60. Holloway F. A., Michaelis R. C., Huerta P. L. Caffeine-phenylethylamine combinations mimic the amphetamine discriminative cue. Life Sci. 36:1985;723-730.
61. Holtzman S. G. Complete, reversible, drug-specific tolerance to stimulation of locomotor activity by caffeine. Life Sci. 33:1983;779-787.
62. Horger B. A., Wellman P. J., Morien A., Davies B. T., Schenk S. Caffeine exposure sensitizes rats to the reinforcing effects of cocaine. NeuroReports. 53:1991;53-56.
63. Howell L. L. Comparative effects of caffeine and selective phosphodiesterase inhibitors on respiration and behavior in rhesus monkeys. J. Pharmacol. Exp. Ther. 266:1993;894-902.
64. Howell L. L., Byrd L. D. Effects of CGS 15943, a non-xanthine adenosine antagonist, on behavior in the squirrel monkey. J. Pharmacol. Exp. Ther. 267:1993;432-439.
65. Hughes J. R., Oliveto A. H., Bickel W. K., Higgins S. T., Badger G. J. The ability of low doses of caffeine to serve as reinforcers in humans. A replication Exp. Clin. Pharmacol. 3:1995;358-363.
66. Jacobs D., Silverstone T. Dextroamphetamine-induced arousal in human subjects as a model for mania. Psychol. Med. 16:1986;323-329.
67. Jiang H., Jackson-Lewis V., Muthane U., Dollison A., Ferreira M., Espinosa A., Parsons B., Przedborski S. Adenosine receptor antagonists potentiate dopamine receptor agonist-induced rotational behavior in 6-hydroxydopamine-lesioned rats. Brain Res. 613:1993;347-351.
68. Johanson C. E., Uhlenhuth E. H. Drug preference and mood in humans. d-Amphetamine Psychopharmacology. 71:1980;275-279.
69. Jonsson L. Pharmacological blockade of amphetamine effects of amphetamine in amphetamine dependent subjects. Eur. J. Clin. Pharmacol. 4:1972;206-211.
70. Josselyn S. A., Beninger R. J. Behavioral effects of intrastriatal caffeine mediated by adenosinergic modulation of dopamine. Pharmacol. Biochem. Behav. 39:1991;97-103.
71. Kamien J. B., Bickel W. K., Hughes J. R., Higgins S. T., Smith B. J. Drug discrimination by humans compared to nonhumans. Current status and future directions Psychopharmacology. 111:1993;259-270.
72. Kuhn D. M., Appel J. B., Greenberg I. An analysis of some discriminative properties of d-amphetamine. Psychopharmacologia. 39:1974;57-66.
73. Kuribara H. Caffeine enhances the stimulant effect of methamphetamine, but may not affect induction of methamphetamine sensitization of ambulation in mice. Psychopharmacology. 116:1994;125-129.
74. Kuribara H., Uchihashi Y. Interactions of opioids with caffeine. Evaluation by ambulatory activity in mice J. Pharm. Pharmacol. 46:1994;141-144.
75. Landolt H. P., Dijk D.-J., Gaus S. E., Borbély A. A. Caffeine reduces low-frequency delta activity in the human sleep EEG. Neuropsychopharmacology. 12:1995;229-238.
76. Leathwood P. D., Pollet P. Diet-induced mood changes in normal populations. J. Psychiatry Res. 17:1983;147-154.
77. Le Moine C., Normand E., Guitteny A. F., Fouque B., Teoule R., Bloch B. Dopamine receptor gene expression by enkephalin neurons in rat forebrain. Proc. Natl. Acad. Sci. USA. 87:1990;230-234.
78. Lieberman H. R., Wurtman R. J., Emde G. G., Roberts C., Covielle I. L. G. The effects of low doses of caffeine in human performance and mood. Psychopharmacology. 92:1987;308-312.
79. McNamara C., Wellman P. J., Schenk S. Dopamine mediation of reinstatement of extinguished cocaine-taking produced by caffeine. Presented at College on Problems of Drug Dependence:1995;57th. Annual Scientific Meeting, June 10-15.
80. Mekhail-Ishak I., Lavoie P. A., Sharkawi M. Effects of caffeine and cyclic adenosine 3′5′-monophosphate on adenosine triphosphate-dependent calcium uptake by lysed brain synaptosomes. Brain Res. 426:1987;62-68.
81. Misra A. L., Vadlamani N. L., Pontani R. B. Effect of caffeine on cocaine locomotor stimulant activity in rats. Pharmacol. Biochem. Behav. 24:1986;761-764.
82. Morgan M. E., Vestal R. E. Methylxanthine effects on caudate dopamine release as measured by in vivo electrochemistry. Life Sci. 45:1989;2025-2039.
83. 2 receptors stimulate c-fos expression in striatal neurons of 6-hydroxydopamine-lesioned rats. Neuroscience. 67:1995;49-55.
84. Mukhopadhyay S., Poddar M. K. Caffeine-induced locomotor activity. Possible involvement of GABAergic-dopaminergic-adenosinergic interaction Neurochem. Res. 20:1995;39-44.
85. Mumford G. K., Evans S. M., Kaminski B. J., Preston K. L., Sannerud C. A., Silverman K., Griffiths R. R. Discriminative stimulus and subjective effects of theobromine and caffeine in humans. Psychopharmacology. 115:1994;1-8.
86. Mumford G. K., Holtzman S. G. Qualitative differences in the discriminative stimulus effects of low and high doses of caffeine in the rat. J. Pharmacol. Exp. Ther. 258:1991;857-865.
87. Nehlig A., Daval J.-L., Debry G. Caffeine and the central nervous system. Mechanisms of action, biochemical, metabolic and psychostimulant effects Brain Res. Rev. 17:1992;139-170.
88. Nurnberger J. I., Simmons-Alling S., Kessler L., Jimerson S., Schreiber J., Hollander E., Tamminga C. A., Nadi N. S., Goldstein D. S., Gershon E. S. Separate mechanisms for behavioral, cardiovascular, and hormonal responses to dextroamphetamine in man. Psychopharmacology. 84:1984;200-204.
89. Oliveto A. H., Bickel W. K., Hughes J. R., Shea P. J., Higgins S. T., Fenwick J. W. Caffeine drug discrimination in humans. Acquisition, specificity and correlation with self-reports J. Pharmacol. Exp. Ther. 261:1992;885-894.
90. Oliveto A. H., Bickel W. K., Hughes J. R., Terry S. Y., Higgins S. T., Badger G. J. Pharmacological specificity of the caffeine discriminative stimulus in humans. Effects of theophylline, methylphenidate and buspirone Behav. Pharmacol. 4:1993;237-246.
91. Powell K. R., Holtzman S. G. D1 and D2 dopamine receptor involvement in the discriminative-stimulus effects of caffeine in rats. Behav. Pharmacol. 7(suppl. 1):1996;90-91.
92. Preston K. L., Sullivan J. T., Berger P., Bigelow G. E. Effects of cocaine alone and in combination with mazindol in human cocaine abusers. J. Pharmacol. Exp. Ther. 267:1993;296-307.
93. Preston K. L., Sullivan J. T., Strain E., Bigelow G. E. Effects of cocaine alone and in combination with bromocriptine in human cocaine abusers. J. Pharmacol. Exp. Ther. 262:1992;279-291.
94. Rogers P. J., Richardson N. J., Elliman N. A. Overnight caffeine abstinence and negative reinforcement of preference of caffeine-containing drinks. Psychopharmacology. 120:1995;457-462.
95. Rush C. R., Sullivan J. T., Griffiths R. R. Intravenous caffeine in stimulant drug abusers. Subjective reports and physiological effects J. Pharmacol. Exp. Ther. 273:1995;351-358.
96. Sattin A., Rall T. W. The effect of adenosine and adenine nucleotides on the cyclic adenosine 3′5′-phosphate content of guinea pig cerebral cortex slices. Mol. Pharmacol. 6:1970;13-23.
97. Sawynok J., Yaksh T. L. Caffeine as an analgesic adjuvant. A review of pharmacology and mechanisms of action Pharmacol. Rev. 45:1993;43-82.
98. Schechter M. D. Caffeine potentiation of amphetamine. Implication for hyperkinesis therapy Pharmacol. Biochem. Behav. 6:1977;359-361.
99. Schenk S., Valadez A., Horger B. A., Snow S., Wellman P. J. Interactions between caffeine and cocaine in tests of self-administration. Behav. Pharmacol. 5:1994;153-158.
100. Schiffman S. N., Jacobs O., Vanderhaeghen J.-J. RDC8) is expressed by enkephalin but not by substance P neurons. An in situ hybridization histochemistry study J. Neurochem. 57:1991;1062-1067.
101. Schildkraut J. J., Watson R. K., Draskoczy P. R. Amphetamine withdrawal. Depression and MHPG excretion Lancet. 2:1971;485-486.
102. Schuh K. J., Griffiths R. R. Caffeine reinforcement. Role of withdrawal In. Harris, L. S., ed. Problems of drug dependence. NIDA Research Monograph. Washington, DC: US Government Printing Office. 162:1996;292.
103. Sherer M. A., Kumor K. M., Jaffe J. H. Effects of intravenous cocaine are partially attenuated by haloperidol. Psychiatry Res. 27:1989;117-125.
104. Silverman K., Griffiths R. R. Low-dose caffeine discrimination and self-reported mood effects in normal volunteers. J. Exp. Anal. Behav. 57:1992;91-107.
105. Silverman K., Mumford G. K., Griffiths R. R. Enhancing caffeine reinforcement by behavioral requirement following drug ingestion. Psychopharmacology. 114:1994;424-432.
106. Snel J. Coffee and caffeine, sleep and wakefulness. Garattini S. Caffeine, coffee, and health. 1993;255-290 Raven Press, New York.
107. Snyder S. H., Katims J. J., Annau A., Bruns R. F., Daly J. W. Adenosine receptors in the central nervous system. Relationship to the central actions of methylxanthines Life Sci. 28:1981;2083-2097.
108. Spealman R. D. Psychomotor stimulant effects of methylxanthines in squirrel monkeys. Relation to adenosine antagonism Psychopharmacology. 95:1988;19-24.
109. Stern K. N., Chait L. D., Johanson C. E. Reinforcing and subjective effects of caffeine in normal human volunteers. Psychopharmacology. 98:1989;81-88.
110. Stringer K. A., Watson W. A. Caffeine withdrawal symptoms. Am. J. Emerg. Med. 5:1987;469.
111. Stromberg U., Waldeck B. Further studies on the behavioral and biochemical interaction between caffeine and L-dopa. J. Neural Transm. 34:1973;241-252.
112. Sutherland E. W., Rall T. W. Fractionation and characterization of a cyclic adenine ribonucleotide formed by tissue particles. J. Biol. Chem. 232:1958;1077-1091.
113. Swerdlow N. R., Vaccarino F. J., Amalric M., Koob G. F. The neural substrates for the motor-activating properties of psychostimulants. A review of recent findings Pharmacol. Biochem. Behav. 25:1986;233-248.
114. Trotta E. E., Freire G. L. Inhibition by caffeine of calcium uptake by brain microsomal vesicles. J. Pharm. Pharmacol. 214:1980;670-674.
115. Wachtel H. Characteristic behavioral alterations in rats induced by rolipram and other selective adenosine cyclic 3′5′-monophosphate phosphodiesterase inhibitors. Psychopharmacology. 77:1982;309-316.
116. Walsh S. L., Preston K. L., Sullivan J. T., Fromme R., Bigelow G. E. Fluoxetine alters the effects of intravenous cocaine in humans. J. Clin. Pharmacol. 14:1995;396-407.
117. Watanabe H., Ikeda M., Watanabe K. Properties of rotational behavior produced by methylxanthine derivatives in mice with unilateral striatal 6-hydroxydopamine-induced lesions. J. Pharm. Dyn. 4:1981;301-307.
118. Watanabe H., Uramoto H. Caffeine mimics dopamine receptor agonists without stimulation of dopamine receptors. Neuropharmacology. 25:1986;577-581.
119. Watson R., Bakos L., Compton P., Gawin F. Cocaine use and withdrawal. The effect on sleep and mood Am. J. Drug Alcohol Abuse. 18:1992;21-28.
120. Watson R., Hartman E., Schildkraut J. J. Amphetamine withdrawal. Affective state, sleep patterns and MHPG excretion Am. J. Psychiatry. 129:1972;263-269.
121. Weiss B., Hait W. N. Selective cyclic nucleotide phosphodiesterase inhibitors as potential therapeutic agents. Annu. Rev. Pharmacol. Toxicol. 17:1977;441-477.
122. White B. C., Keller G. E. Caffeine pretreatment. Enhancement and attenuation of d-amphetamine-induced activity Pharmacol. Biochem. Behav. 20:1984;383-386.
123. White B. C., Simpson C. C., Adams J. E., Harkins D. Monoamine synthesis and caffeine-induced locomotor activity. Neuropharmacology. 17:1978;511-513.
124. Winter J. C. Caffeine-induced stimulus control. Pharmacol. Biochem. Behav. 15:1981;157-159.
125. Worley C. M., Valadez A., Schenk S. Reinstatement of extinguished cocaine-taking behavior by cocaine and caffeine. Pharmacol. Biochem. Behav. 48:1994;217-221.